



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

File No. 14149-4"US" FC/ntb

ASSISTANT COMMISSIONER FOR PATENTS,  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Box 509  
JC511 U.S. PTO  
09/678303  
10/03/00

Inventor(s): **Louis-Philippe Vézine et al.**

For: **PROMOTER FOR REGULATING EXPRESSION OF  
FOREIGN GENES**

Your petitioner prays that letters patent may be granted for the invention set forth in the enclosed specification including a disclosure, claims and declaration.

Enclosed are :

Combined Declaration (unexecuted)  
 An additional copy of this sheet and an Assignment of the Invention to \_\_\_\_\_  
 A certified copy of \_\_\_\_\_ on the basis of which the benefit of priority under 35 U.S.C. 119 is claimed.  
 Declaration of small entity status.

	No. filed	Number Extra	Rate	Basic Fee \$345.00
Total Claims	8		9.00	-
Multiple Dependency Fee	-	-		-
Independent Claims	1	-	39.00	-
Filing Fees				\$345.00
Assignment Fee				
Total				<b>\$345.00</b>

A cheque No. 008135, including the amount of \$345.00 to cover the Government Assignment, Filing and Extra Claims Fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Account No. 19-5113.

  
\_\_\_\_\_  
October 2, 2000 \_\_\_\_\_  
\_\_\_\_\_  
Attorney or Agents of the Applicant  
France Côté  
Registration No. 37,037  
Tel. No. (514) 845-7126

**SWABEY OGILVY RENAULT**  
Suite 1600,  
1981 McGill College Ave.  
Montreal, Quebec  
Canada H3A 2Y3

Applicant or Patentee: Louis-Philippe VÉZINA et al.  
Serial or Patent No.: \_\_\_\_\_ Atty. Dkt. No.: 14149-4US FC/ntb  
Filed or Issued: \_\_\_\_\_  
For: PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES

**VERIFIED STATEMENT (DECLARATION) BY A NON-INVENTOR  
SUPPORTING A CLAIM BY ANOTHER FOR SMALL ENTITY STATUS**

I hereby declare that I am making this verified statement to support a claim by MEDICAGO INC. for small entity status for purposes of paying reduced fees to the United States Patent and Trademark Office, regarding the invention entitled PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES by inventor(s) Louis-Philippe Vézina; and Marc-André D'Aoust described in:

the specification filed herewith  
 application serial no. \_\_\_\_\_, filed \_\_\_\_\_  
 patent no. \_\_\_\_\_, issued \_\_\_\_\_.

I hereby declare that the said inventors qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying fees to the United States Patent and Trademark Office.

I hereby declare that the said inventors have not assigned, granted, conveyed or licensed and are under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e), except as indicated below.

Each person, concern or organization to which said inventors have assigned, granted, conveyed, or licensed or are under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

no such person, concern, or organization  
 persons, concerns or organizations listed below\*

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME MEDICAGO INC.

ADDRESS 2480, rue Hochelaga, Sainte-Foy, Québec, CANADA G1K 7P4

INDIVIDUAL  SMALL BUSINESS CONCERN  NONPROFIT ORGANIZATION

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

INDIVIDUAL  SMALL BUSINESS CONCERN  NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING France Côté

ADDRESS OF PERSON SIGNING 102 de la Moselle, St-Lambert, Québec, Canada J4S 1W2

SIGNATURE: France Côté DATE: October 2, 2000

## **PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES**

### **BACKGROUND OF THE INVENTION**

#### **(a) Field of the Invention**

5 The invention relates to a promoter for regulating expression of foreign genes in a transgenic organism, more specifically in a leaf-specific manner in transgenic plants.

#### **(b) Description of Prior Art**

10 Genetic transformation of microbes have been used for more than 15 years to produce useful recombinant molecules, and applications in the pharmaceutical, cosmeceutical and dermaceutical industries are being currently exploited. This technology has expanded from microbes to plants and animals in the last ten years with the development of techniques required to adapt this general concept to complex eukaryotic 15 organisms. Basically a gene encoding for a protein of interest or a gene encoding for an enzyme responsible for a modification of a metabolic pathway that leads to a molecule of interest, is linked in an appropriate fashion to cis-and trans-acting regulatory sequences, and transferred to a target cell where it is incorporated in the molecular machinery (in a transitory or stable fashion). The transgenic cell, or a tissue or organism 20 regenerated from the transgenic cell will then perform transcription and translation of the transgene and therefore be enabled to accumulate the protein of interest or to perform the new metabolic reaction through the activity of the enzyme of interest.

25 The emerging industry of molecular farming is one of the most promising industry of the coming century. Its promise is to provide safe and renewable molecule factories for the industry. Among the applications that are currently developed are the production of low-cost monoclonal antibodies for therapeutic and diagnostic uses, the production of unlimited 30 amounts of hormones, cytokines and other bio-active molecules for the treatment of chronic or lethal diseases, the production of bio-safe substitutes for various blood components, the production of unlimited amounts of processing enzymes for the food and pulp industry, the production of low-cost enzymes for waste treatments, and the production 35 of safe bio-active molecules for the cosmetic industry.

Limitations to the application of this technology has often come from the inability of transgenic organisms to accumulate adequate amounts of the recombinant product, as a result of low transcription rates, improper splicing of the messenger, instability of the foreign mRNA, poor 5 translation rates, hyper-susceptibility of the recombinant protein to the action of endogenous proteases or hyper-susceptibility of the recombinant organism to the foreign protein which result in improper and limited growth or in the worst cases, in strong deleterious effects to the host organism. Inadequacy of production level has a direct impact on the development of 10 applications when profit margins are narrow, or when treatment and/or disposal of residual matter causes bio-safety or environmental problems. Improvement of the accumulation level of the desired recombinant product thus appears to be one critical factor that warrants commercialization of 15 many applications of molecular farming.

Photosynthesis is a metabolic reaction of paramount importance in the living world. It is performed by most land plants and algae, and by 20 some bacteria. This overall reaction involves a complex assembly of electron transfer proteins spatially arranged within the thylakoid membrane system located in the chloroplast of leaf cells. This electron transport chain is coupled at one end with the photosynthetic antennae, which comprise a 25 variety of macro-molecules, including one molecule common to all photosynthetic organism, chlorophyll, and at the other end, to the enzymes involved in NADPH and ATP synthesis, and to the Calvin cycle, involved in coupling the release of energy from NADPH and ATP with the fixation of gaseous carbon dioxide into organic molecules. Among the proteins involved in the overall photosynthetic reaction, one, Ribulose biphosphate 30 carboxylase (Rubisco), is the most abundant protein on earth.

Photosynthesis is thus what leaf cells are dedicated to perform, and there is an obvious interest to use promoters of genes involved in 35 such prominent tissue-specific metabolic activity when building strong leaf-specific expression cassettes for applications in plant biotechnology.

Many of the peptidic constituents of the photosynthetic apparatus are encoded by genes present in the chloroplastic genome; as an example, the heavy subunit of Rubisco, which bears the catalytic sites for CO<sub>2</sub> fixation, is encoded by a chloroplastic gene. However, the small

subunit of this enzyme is encoded by a nuclear gene, and thus the Rubisco holo-protein is made of subunits encoded by two different genomes. For obvious reasons, there has been a great interest in trying to use Rubisco promoters to control transcription of transgenes in leaves of 5 transgenic plants. The promoter has been extensively characterized and its use in expression vectors is protected by United States Patent No. 4,962,028.

It would be highly desirable to be provided with a promoter for regulating expression of foreign genes in a transgenic organism, more 10 specifically in transgenic plants.

### **SUMMARY OF THE INVENTION**

One aim of the present invention is to provide with a promoter for regulating expression of foreign genes in a transgenic organism, more 15 specifically in transgenic plants.

In accordance with one embodiment of the present invention, there is provided a promoter for regulating expression of foreign genes in transgenic organisms, which comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3 and functional 20 fragments or derivatives thereof, wherein said promoter is adapted to be operationally located with respect to said foreign gene for expression of said gene.

The preferred promoter of the present invention has a sequence 25 selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3.

Preferably, the organism is a plant.

Preferably, the promoter of the present invention may be modulated by the presence or absence of light.

30 The preferred plant is a dicot, a monocot or a gymnosperm.

In accordance with another embodiment of the present invention, there is provided a method of regulating expression of foreign genes in transgenic organisms, comprising the steps of:

35 a) preparing a transgenic organism using an expression construct consisting of at least a promoter of the present invention, and an

ORF of a gene, wherein said promoter is operationally located with respect to said gene for expression of said gene.

For the purpose of the present invention the following terms are defined below.

5 The expression "functional fragments or derivatives thereof" is intended to mean any derivative or fragment of sequences SEQ ID NOS:1-3 which allow for an equivalent level of expression of a foreign gene as the promoter of the present invention set forth in SEQ ID NOS:1-3.

## DETAILED DESCRIPTION OF THE INVENTION

Following is a detailed description of the method used to generate transgenic alfalfa lines that can be regulated in their expression of a reporter gene.

15 In this embodiment, a promoter having the sequence set forth in  
SEQ ID NOS:1-3 was then ligated to a reporter gene and a terminator, and  
this construct was inserted in suitable plant expression vectors for DNA  
bombardment onto alfalfa leaves and for *Agrobacterium* mediated DNA  
transfer as described by Desgagnés et al. (1995, *Plant Cell Tissue Organ*  
20 *Cult.* 42:129-140). These two DNA transfer methods were used to  
demonstrate that expression of the reporter gene can be modulated by  
light.

## Materials and Methods

## DNA sequencing

DNA sequencing was performed as described by Sanger et al (1977, *P.N.A.S. USA*, 74:5643-5647).

The resulting promoters of the present invention have the sequence as set forth in SEQ ID NOS: 1 to 3.

## Construction of expression cassettes and vectors

The cassettes for expression analysis using the GUS reporter gene were assembled as follows. A promoterless GUS cassette was digested from pBI101 with HindIII and EcoRI, and was inserted into the

HindIII and EcoRI sites of the pUC19 polycloning site. The resulting plasmid was named pBI201 and was used for further constructs. Various deletion fragments of pGPlas3-2 were transcriptionally and translationally fused at the 5'terminus of the GUS reporter gene in pBI201 and these 5 were used for transitory expression studies using DNA bombardment. Upon identification of the adequate deletion fragment, it was subcloned into a binary plant expression vector such as pBI101 (Clonetech). These recombinant plasmids were used for stable integration through *A. tumefaciens* infection as described below.

10

#### ***Agrobacterium*-mediated DNA transfer and regeneration of transgenic lines**

15

The recombinant plasmids were introduced into *Agrobacterium tumefaciens* strain LBA4404 by electroporation as described in Khoudi et al (1999, *Biotechnol. Bioeng.*, 64:135-143). Selected *Agrobacterium* strains were then co-cultivated with leaf disks from genotype C5-1 for 4 days in the absence of selection pressure (kanamycin). Following this incubation period, leaf disks were washed and pampered, and then allowed to form calli onto medium B5H. Calli were then transferred for 21 days on SH medium for embryo induction and for 28 days on BOi2Y for embryo development. Torpedo-shaped embryos were removed from BOi2Y and placed on MS medium for regeneration. Kanamycin was present in all cultivation medium except for co-cultivation and regeneration on MS. This method is described in length in Desgagnés et al (1995, *Plant Cell Tissue Organ Cult.* 42:129-140). Rooted plantlets were grown to maturity in the 20 25 greenhouse.

30

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the 35 appended claims.

RECEIVED  
U.S. PATENT AND TRADEMARK OFFICE  
APR 11 1999

**WHAT IS CLAIMED IS:**

1. A promoter for regulating expression of foreign genes in transgenic organisms, which comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3 and functional fragments or derivatives thereof, wherein said promoter is adapted to be operationally located with respect to said foreign gene for expression of said gene.
2. The promoter of claim 1, wherein said promoter is modulated for transcriptional expression of said gene by presence or absence of light
3. The promoter of claim 1, wherein the promoter has a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3.
4. The promoter of claim 1, wherein said organism is a plant.
5. The promoter of claim 4, wherein said plant is a dicot, a monocot or a gymnosperm.
6. A method of regulating expression of foreign genes in transgenic organisms, comprising the steps of:
  - a) preparing a transgenic organism using an expression construct consisting of at least a promoter of claim 1, and an ORF of a gene, wherein said promoter is operationally located with respect to said gene for expression of said gene.
7. The method of claim 6, wherein said organism is a plant.
8. The method of claim 7, wherein said plant is a dicot, a monocot or a gymnosperm.

## **ABSTRACT OF THE INVENTION**

The present invention relates to a promoter for regulating expression of foreign genes in transgenic organisms, which comprises a promoter having the identifying characteristics of a promoter having a sequence selected from the group consisting of sequences set forth in SEQ ID NOS:1 to 3 and functional fragments or derivatives thereof, wherein said promoter is adapted to be operationally located with respect to said foreign gene for expression of said gene.

## SEQUENCE LISTING

<110> VÉZINA, Louis-Philippe  
 D'AOUST, Marc-André  
 MEDICAGO Inc.

<120> PROMOTER FOR REGULATING EXPRESSION OF  
 FOREIGN GENES

<130> 14149-4 "US"

<150> US 60/157,129  
 <151> 1999-10-04

<160> 3

<170> FastSEQ for Windows Version 3.0

<210> 1  
 <211> 1350  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Sequence to be used as a Promoter for regulating  
 expression

<400> 1

cgacggcccg ggctggata tttatatgtt gtcaaataac tcaaaaacca taaaagtta	60
agttagcaag tgtgtacatt tttatttgaa caaaaatatt cacctactac tggataat	120
cattattaaa cattagaga aagaaatatg gatgataaga acaagagtag tgatatttg	180
acaacaattt tggcaaca tttgagaaaa tttgttgtt ctctctttc attggtaaaa	240
aacaatagag agagaaaaag gaagagggag aataaaaaca taatgtgagt atgagagaga	300
aagggttaca aaagttgtac caaaaatattt gtacaaatattt cattgaggaa tttgacaaaa	360
gctacacaaa taagggtaa ttgctgtaaa taaataagga tgacgcatta gagagatgt	420
ccatttagaga atttttggca agtcattaaa aagaaagaat aaatttattt taaaattttaa	480
agttgagtca ttgttattttt catgtgatta ttaatgttataat tgatgaaaga gttggat	540
agttgttata gtaatttagaa ttgggtgtca aattttatgg gacattttat cttttccat	600
atattggccc atagagtcag ttaacttcatt tttatatttc atagatcaaa taagagaaat	660
aacggatat taatccctcc aaaaaaaaaa aacggatat ttactaaaaa atctaagcca	720
cgtaggagga taacatccaa tccaaaccaat cacaacaatc ctgtatggat aacccactt	780
aagcccacgc actctgtggc acatctacat tatctaaatc acacattttt ccacacatct	840
gagccacaca aaaaccaatc cacatcttta tcacccatcc tataaaaaat cacactttgt	900
gagtcacac ttgttattccc ttcaaaacaca tacaaagaga agagactaat taattaat	960
atcatcttgc gaaaaatgg ccaccgttac ttccaccacc gttgttattc catcattcac	1020
aggcccttaag gcaaacgc当地 gcaaaatggccatgttccatgttccaa cttcaacttc	1080
tcaattgcca aggctttgttgc tcaagatccc cctcaaaagac tttggatgttgc tggatgttgc	1140
cactgctgca agtgcattgt tagcttagcaa tgcccttgc当地 gttgaatgttgc tgcttggatgttgc	1200
tagtgtatgggg ggtttggctt ttgttccaaa caatttcaca gtgaacgc当地 gagacacccat	1260
tacattcaag aacaatgctg gttttccatca caacgttatac ttcatgttcaag acgagatcc	1320
aagcgggggtt gatgctgcaa tcgaattcccc	1350

<210> 2  
 <211> 971  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Sequence to be used as a Promoter for regulating  
 expression

<400> 2

cgggctggta	tat	tttatatg	ttgtcaaaata	actcaaaaac	cataaaagtt	taagtttagca	60
agtgtgtaca	t	tttttattt	aaacaaaata	ttcacctact	actgttataa	atcattatta	120
aacatttagag	taa	agaaata	tggatgataa	gaacaagagt	agtatattt	tgacaacaat	180
tttgtgcaa	cattt	gagaa	aattttgtt	ttctctctt	tcatggta	aaaacaatag	240
agagagaaaa	agg	aaagagg	agaataaaaa	cataatgtga	gtatgagaga	gaaagtgt	300
caaaagttgt	acc	aaaat	ttgtacaaat	atcattgagg	aatttgacaa	aagctacaca	360
aataagggtt	aatt	tgctgt	aataaataag	gatgacgcat	tagagagatg	taccattaga	420
gaatttttgg	caag	tcat	aaaagaaaga	ataaattatt	tttaaaatta	aaagttgagt	480
catttgatta	aac	atgtgt	tatttaatga	attgtgaaa	gagttggatt	aaagttgtat	540
tagtaattag	aattt	gggtgt	caaatttaat	ttgacattt	atctttcct	atatattgcc	600
ccatagagtc	agt	taact	ttttatatt	tcatagatca	aataagagaa	ataacggtat	660
attaatccct	cc	aaaaaaa	aaaacggtat	atttactaaa	aaatctaagc	cacgttaggag	720
gataacatcc	aat	ccaa	atcacaacaa	tcctgtatgag	ataacccact	ttaagccac	780
gcactctgtg	gc	acatctac	attatctaaa	tcacacattc	ttccacacat	ctgagccaca	840
caaaaaccaa	tcc	acatcttt	tatcaccat	tctataaaaa	atcacacttt	gtgagtc	900
actttgattc	c	tttcaaa	catacaaaga	gaagagacta	attaattaat	taatcatctt	960
gagagaaaaat	g						971

<210> 3  
 <211> 731  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Sequence to be used as a Promoter for regulating  
 expression

<400> 3

agagagaaaa	agg	aaagaggg	agaataaaaa	cataatgtga	gtatgagaga	gaaagtgt	60
caaaagttgt	acc	aaaat	ttgtacaaat	atcattgagg	aatttgacaa	aagctacaca	120
aataagggtt	aatt	tgctgt	aataaataag	gatgacgcat	tagagagatg	taccattaga	180
gaatttttgg	caag	tcat	aaaagaaaga	ataaattatt	tttaaaatta	aaagttgagt	240
catttgatta	aac	atgtgt	tatttaatga	attgtgaaa	gagttggatt	aaagttgtat	300
tagtaattag	aattt	gggtgt	caaatttaat	ttgacattt	atctttcct	atatattgcc	360
ccatagagtc	agt	taact	ttttatatt	tcatagatca	aataagagaa	ataacggtat	420
attaatccct	cc	aaaaaaa	aaaacggtat	atttactaaa	aaatctaagc	cacgttaggag	480
gataacatcc	aat	ccaa	atcacaacaa	tcctgtatgag	ataacccact	ttaagccac	540
gcactctgtg	gc	acatctac	attatctaaa	tcacacattc	ttccacacat	ctgagccaca	600
caaaaaccaa	tcc	acatcttt	tatcaccat	tctataaaaa	atcacacttt	gtgagtc	660
actttgattc	c	tttcaaa	catacaaaga	gaagagacta	attaattaat	taatcatctt	720
gagagaaaaat	g						731

<b>COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) AND POWER OF ATTORNEY</b>		Attorney Docket Number	14149-4US FC
		First Named Inventor	Louis-Philippe Vézina et al.
		<i>Complete if known</i>	
		Application Number	
		Filing Date	
		Group Art Unit	
		Examiner Name	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing      OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16(e)) required)			

**As a below named inventor, I hereby declare that:**

My residence, post office address and citizenship are as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**PROMOTER FOR REGULATING EXPRESSION OF FOREIGN GENES**

the specification of which

is attached hereto.

OR

was filed on \_\_\_\_\_

(mm/dd/yyyy)

as United States Application Number or PCT International Application Number \_\_\_\_\_

and was amended on \_\_\_\_\_ (if applicable).

(mm/dd/yyyy)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
60/157,129	10/04/1999	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

**COMBINED DECLARATION FOR UTILITY OR DESIGN  
PATENT APPLICATION (37 CFR 1.63) AND POWER OF ATTORNEY**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent Trademark Office connected therewith:

Customer Number: **020988**



**020988**

PATENT AND TRADEMARK OFFICE

Direct all correspondence to:



**020988**

PATENT AND TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**Name of sole or First Inventor:**

A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Louis-Philippe

VÉZINA

Inventor's Signature

Date

Residence: City

Neuville State Québec Country Canada Citizenship Canadian

Post Office Address

206, Route 138

City

Neuville Province or State Québec Postal Or Zip G0A 2R0 Country Canada

Additional inventors are being named on the

supplemental Additional Inventor(s) PTO/SB/02A attached hereto.

COMBINED DECLARATION FOR UTILITY OR DESIGN  
PATENT APPLICATION (37 CFR 1.63) AND POWER OF ATTORNEY

PTO/SB/02A (3-97)

**DECLARATION**

**ADDITIONAL INVENTOR(S)**  
Supplemental Sheet  
Page 1 of 1

**Name of Additional Joint Inventor, if any:**

Given Name (first and middle [if any])

Family Name or Surname

Marc-André

D'AOUST

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence:  
City Québec State Québec Country Canada Citizenship Canadian

Post Office Address 939, avenue Manrière, App. 2

City Québec Province or State Québec Postal Code Or Zip G1S 2W9 Country Canada

**Name of Additional Joint Inventor, if any:**

A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence:  
City \_\_\_\_\_ State \_\_\_\_\_ Country \_\_\_\_\_ Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

City \_\_\_\_\_ Province or State \_\_\_\_\_ Postal Code Or Zip \_\_\_\_\_ Country \_\_\_\_\_

**Name of Additional Joint Inventor, if any:**

A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Inventor's Signature \_\_\_\_\_ Date \_\_\_\_\_

Residence:  
City \_\_\_\_\_ State \_\_\_\_\_ Country \_\_\_\_\_ Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

City \_\_\_\_\_ Province or State \_\_\_\_\_ Postal Code Or Zip \_\_\_\_\_ Country \_\_\_\_\_

Additional Inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) PTO/SB/02A attached hereto.